![Pieter van der Meijden](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Pieter van der Meijden
Directeur/Membre du Conseil chez ISA Pharmaceuticals BV
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Cornelis J. M. Melief | M | - |
ISA Pharmaceuticals BV
![]() ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | - |
Gerben Moolhuizen | M | 57 |
ISA Pharmaceuticals BV
![]() ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | - |
Markwin P. Velders | M | 59 |
ISA Pharmaceuticals BV
![]() ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | 5 ans |
Chandra Paul Leo | M | 53 |
i-Optics BV
![]() i-Optics BV Medical SpecialtiesHealth Technology i-Optics BV develops and produces eye diagnosis and therapeutic solutions. Its lead product, the EasyScan, that provides non-mydriatic retina imaging camera for the diagnosis of diabetic retinopathy and macular degeneration. The firm engages in the development and marketing of retina and cornea imaging solutions. The company was founded by Michiel Mensink and is headquartered in The Hague, the Netherlands. | - |
Bart Bergstein | M | - |
ISA Pharmaceuticals BV
![]() ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | - |
Jeroen Cammeraat | M | 59 |
i-Optics BV
![]() i-Optics BV Medical SpecialtiesHealth Technology i-Optics BV develops and produces eye diagnosis and therapeutic solutions. Its lead product, the EasyScan, that provides non-mydriatic retina imaging camera for the diagnosis of diabetic retinopathy and macular degeneration. The firm engages in the development and marketing of retina and cornea imaging solutions. The company was founded by Michiel Mensink and is headquartered in The Hague, the Netherlands. | 14 ans |
Hendrik Zonnenberg | M | - |
ISA Pharmaceuticals BV
![]() ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | - |
Joris Vogels | M | - |
i-Optics BV
![]() i-Optics BV Medical SpecialtiesHealth Technology i-Optics BV develops and produces eye diagnosis and therapeutic solutions. Its lead product, the EasyScan, that provides non-mydriatic retina imaging camera for the diagnosis of diabetic retinopathy and macular degeneration. The firm engages in the development and marketing of retina and cornea imaging solutions. The company was founded by Michiel Mensink and is headquartered in The Hague, the Netherlands. | - |
Willem-Jan Krebber | M | - |
ISA Pharmaceuticals BV
![]() ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Pays-Bas | 9 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Pieter van der Meijden
- Réseau Personnel